Literature DB >> 28181283

Transplantation in thalassemia: Revisiting the Pesaro risk factors 25 years later.

Emanuele Angelucci1, Federica Pilo2, Thomas D Coates3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28181283     DOI： 10.1002/ajh.24674

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  10 in total

1.  Complication free survival long-term after hemopoietic cell transplantation in thalassemia.

Authors:  Emanuele Angelucci
Journal:  Haematologica       Date:  2018-07       Impact factor: 9.941

Review 2.  New therapeutic targets in transfusion-dependent and -independent thalassemia.

Authors:  M Domenica Cappellini; Irene Motta
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.

Authors:  Roswitha Lüftinger; Natalia Zubarovskaya; Christina Peters; Arjan Lankester; Selim Corbacioglu; Jacques-Emmanuel Galimard; Annamaria Cseh; Elisabeth Salzer; Franco Locatelli; Mattia Algeri; Akif Yesilipek; Josu de la Fuente; Antonella Isgrò; Amal Alseraihy; Emanuele Angelucci; Frans J Smiers; Giorgia La La Nasa; Marco Zecca; Tunc Fisgin; Emel Unal; Katharina Kleinschmidt
Journal:  Ann Hematol       Date:  2022-01-09       Impact factor: 3.673

Review 4.  Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.

Authors:  Irene Motta; Rayan Bou-Fakhredin; Ali T Taher; Maria Domenica Cappellini
Journal:  Drugs       Date:  2020-07       Impact factor: 9.546

Review 5.  Curing Hemoglobinopathies: Challenges and Advances of Conventional and New Gene Therapy Approaches.

Authors:  Irene Motta; Valentina Ghiaccio; Andrea Cosentino; Laura Breda
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-11-01       Impact factor: 2.576

Review 6.  Selecting β-thalassemia Patients for Gene Therapy: A Decision-making Algorithm.

Authors:  Donatella Baronciani; Maddalena Casale; Lucia De Franceschi; Giovanna Graziadei; Filomena Longo; Raffaella Origa; Paolo Rigano; Valeria Pinto; Monia Marchetti; Antonia Gigante; Gian Luca Forni
Journal:  Hemasphere       Date:  2021-04-29

7.  Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia.

Authors:  Isabelle Thuret; Annalisa Ruggeri; Emanuele Angelucci; Christian Chabannon
Journal:  Stem Cells Transl Med       Date:  2022-04-29       Impact factor: 7.655

Review 8.  Innovative Treatments for Rare Anemias.

Authors:  Maria Domenica Cappellini; Alessia Marcon; Bruno Fattizzo; Irene Motta
Journal:  Hemasphere       Date:  2021-06-01

Review 9.  Is the Benefit-Risk Ratio for Patients with Transfusion-Dependent Thalassemia Treated by Unrelated Cord Blood Transplantation Favorable?

Authors:  Tang-Her Jaing
Journal:  Int J Mol Sci       Date:  2017-11-20       Impact factor: 5.923

10.  Should every Patient with MDS get Iron Chelation - Probably Yes.

Authors:  Kanjaksha Ghosh; Kinjalka Ghosh
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-09-01       Impact factor: 2.576
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.